Adolescent; Adult; Aged; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral/genetics; Drug Therapy, Combination; Female; Genotype; HIV Infections/drug therapy; HIV Integrase/genetics; HIV Integrase Inhibitors/adverse effects/therapeutic use; HIV-1; Humans; Male; Middle Aged; Mutation; Organic Chemicals/adverse effects/therapeutic use; Phenotype; Pyrrolidinones; RNA, Viral/blood; Treatment Outcome; Viral Load
Abstract :
[en] BACKGROUND: We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with triple-class drug resistance and in whom antiretroviral therapy had failed. METHODS: We conducted subgroup analyses of the data from week 48 in both studies according to baseline prognostic factors. Genotyping of the integrase gene was performed in raltegravir recipients who had virologic failure. RESULTS: Virologic responses to raltegravir were consistently superior to responses to placebo, regardless of the baseline values of HIV-1 RNA level; CD4 cell count; genotypic or phenotypic sensitivity score; use or nonuse of darunavir, enfuvirtide, or both in optimized background therapy; or demographic characteristics. Among patients in the two studies combined who were using both enfuvirtide and darunavir for the first time, HIV-1 RNA levels of less than 50 copies per milliliter were achieved in 89% of raltegravir recipients and 68% of placebo recipients. HIV-1 RNA levels of less than 50 copies per milliliter were achieved in 69% and 80% of the raltegravir recipients and in 47% and 57% of the placebo recipients using either darunavir or enfuvirtide for the first time, respectively. At 48 weeks, 105 of the 462 raltegravir recipients (23%) had virologic failure. Genotyping was performed in 94 raltegravir recipients with virologic failure. Integrase mutations known to be associated with phenotypic resistance to raltegravir arose during treatment in 64 patients (68%). Forty-eight of these 64 patients (75%) had two or more resistance-associated mutations. CONCLUSIONS: When combined with an optimized background regimen in both studies, a consistently favorable treatment effect of raltegravir over placebo was shown in clinically relevant subgroups of patients, including those with baseline characteristics that typically predict a poor response to antiretroviral therapy: a high HIV-1 RNA level, low CD4 cell count, and low genotypic or phenotypic sensitivity score. (ClinicalTrials.gov numbers, NCT00293267 and NCT00293254.)
Disciplines :
Immunology & infectious disease
Author, co-author :
Cooper, David A
Steigbigel, Roy T
Gatell, Jose M
Rockstroh, Jurgen K
Katlama, Christine
Yeni, Patrick
Lazzarin, Adriano
Clotet, Bonaventura
Kumar, Princy N
Eron, Joseph E
Schechter, Mauro
Markowitz, Martin
Loutfy, Mona R
Lennox, Jeffrey L
Zhao, Jing
Chen, Joshua
Ryan, Desmond M
Rhodes, Rand R
Killar, John A
Gilde, Lucinda R
Strohmaier, Kim M
Meibohm, Anne R
Miller, Michael D
Hazuda, Daria J
Nessly, Michael L
DiNubile, Mark J
Isaacs, Robin D
Teppler, Hedy
Nguyen, Bach-Yen
Moutschen, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Immunopathologie - Transplantation
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services, January 29, 2008. (Accessed June 30, 2008, at http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf.)
Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 2006;296:827-43.
Tozzi V, Zaccarelli M, Bonfigli S, et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther 2006;11:553-60.
Richman DD, Morton S, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393-401.
Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85. [Erratum, N Engl J Med 2003;349:1100.]
Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95.
Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369:1261-9.
Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50.
Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A 2000;97:11244-9.
Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46:125-33.
Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54.
Food and Drug Administration. Antiviral Drugs Advisory Committee Meeting 9/5/2007: Merck, raltegravir tablets NDA 22-145 [applicant presentation]. (Accessed June 30, 2008, at http://www.fda.gov/ohrms/dockets/ac/07/slides/2007- 4314s1-04-merckisaacs.pdf.)
Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78. [Erratum, Lancet 2008;371:116.]
Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine - reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94.
Montaner J, Guimaraes D, Chung J, Gafoor Z, Salgo M, DeMasi R. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials 2005;6:281-90.
Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-60.
MacArthur RD, Novak RM. Maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008;47:236-41.